VRAX

Virax Biolabs Group Limited
CAPPED RATING

Virax Biolabs Group Limited (VRAX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (F). The rating has held at C for 13 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 3.1 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.1
EV / EBITDA 1.0
Rev Growth YoY N/M
Gross Margin 61.9%
Price Return 3M -78.2%
Price Return 12M -94.7%
Catalyst Signal 0.00
Market Cap $823.9K
TTM Revenue $12.4K
Price / Sales 66.3
ROE -78.6%

Historical Factor Score Progression

Held C for 13 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.1) C+ (2.5) C- (2.1) F (0.6) C+ (2.6) C (2.2)
2026-11-08 B- (3.1) C+ (2.5) C- (2.1) F (0.6) C+ (2.6) C (2.2)
2026-11-01 B- (2.9) C+ (2.5) C (2.2) D- (1.0) C+ (2.7) C (2.3)
2026-10-25 B- (2.9) C+ (2.5) C (2.2) D- (0.8) C+ (2.6) C (2.2)
2026-10-18 B- (2.9) C+ (2.5) C (2.2) D- (0.9) C+ (2.6) C (2.2)
Page 1 of 3